Overview
Illexcor Therapeutics is a pre-clinical stage biopharmaceutical company focused on the discovery of oral drugs for sickle cell disease and other small molecule drug discovery pipeline programs. Our lead drug ILX-002 is currently undergoing an IND program following a meeting with FDA and is advancing into a planned first-in-human clinical trial. Illexcor Therapeutics is also evaluating small molecule compounds for other hematologic, respiratory, and inflammatory disorders.